Squibb Company (NYSE:BMY) and Pfizer
Inc. (NYSE:PFE) today announced results of the first human study
evaluating the reversal of the anticoagulant effect of Eliquis
(apixaban) by 4-factor prothrombin complex concentrates (PCCs) in
MetLife, Inc. (NYSE:MET) today announced that it has declared first
quarter 2015 dividends of $0.2500000 per share on the company’s floating
rate non-cumulative preferred stock, Series A (NYSE: METPrA), and
$0.4062500 per share on the company’s 6.50% non-cumulative preferred
stock, Series B (NYSE: METPrB), subject to the final confirmation that
it has met the financial tests specified in the Series A and Series B
preferred stock, which the company anticipates will be made and
announced on or about March 5, 2015, the earliest date permitted in
accordance with the terms of the securities.
Sign-up for QLT Announces Results From Proof-of-Concept Trial With Oral Synthetic cis-Retinoid (QLT091001) in Adult Subjects With Impaired Dark Adaptation and/or Impaired Low Luminance Vision investment picks
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.